专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20070077257A1 Enhanced first generation adenovirus vaccines expressing condon optimized HIV1-Gag, Pol, Nef and modifications 审中-公开
标题翻译：增强的第一代腺病毒疫苗表达宽带优化的HIV1-Gag，Pol，Nef和修饰
公开(公告)号：US20070077257A1
公开(公告)日：2007-04-05
申请号：US11604553
申请日：2006-11-27
申请人： Emilio Emini , Rima Youil , Andrew Bett , Ling Chen , David Kaslow , John Shiver , Timothy Toner , Danilo Casimiro
发明人： Emilio Emini , Rima Youil , Andrew Bett , Ling Chen , David Kaslow , John Shiver , Timothy Toner , Danilo Casimiro
IPC分类号： A61K39/00 , A61K39/12
CPC分类号： A61K39/21 , A61K39/12 , A61K2039/5256 , A61K2039/53 , A61K2039/545 , A61K2039/55555 , C07K14/005 , C12N7/00 , C12N2710/10343 , C12N2710/10351 , C12N2740/16222 , C12N2740/16234 , C12N2740/16322 , C12N2740/16334
摘要： First generation adenoviral vectors and-recombinant adenovirus-based HIV vaccines which contain HIV-1 gag, HIV-1 pol and/or HIV-1 nef polynucleotide pharmaceutical products, and biologically relevant modifications thereof are described. The adenovirus vaccines, when directly introduced into living vertebrate tissue, express the relevant proteins, inducing a cellular immune response which specifically recognizes HIV-1. The exemplified polynucleotides of the present invention are synthetic DNA molecules encoding HIV-1 Gag, HIV-1 Pol, HIV-1 Nef, and derivatives thereof. The adenoviral vaccines of the present invention, alone or in combination, will offer a prophylactic advantage to previously uninfected individuals and/or provide a therapeutic effect by reducing viral load levels within an infected individual, thus prolonging the asymptomatic phase of HIV-1 infection.
摘要翻译：描述了含有HIV-1 gag，HIV-1 pol和/或HIV-1 nef多核苷酸药物产品的第一代腺病毒载体和基于重组腺病毒的HIV疫苗及其生物学相关的修饰。当直接引入活的脊椎动物组织中时，腺病毒疫苗表达相关蛋白质，诱导特异性识别HIV-1的细胞免疫应答。本发明的示例性多核苷酸是编码HIV-1Gag，HIV-1 Pol，HIV-1 Nef的合成DNA分子及其衍生物。本发明的单独或组合的腺病毒疫苗将对先前未感染的个体提供预防优势，和/或通过减少感染个体内的病毒载量水平提供治疗效果，从而延长HIV-1感染的无症状期。

2. 发明申请

US20070054395A1 Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-Gag, Pol, Nef and modifications 审中-公开
标题翻译：表达密码子优化的HIV1-Gag，Pol，Nef和修饰的增强的第一代腺病毒疫苗
公开(公告)号：US20070054395A1
公开(公告)日：2007-03-08
申请号：US11599584
申请日：2006-11-13
申请人： Emilio Emini , Rima Youil , Andrew Bett , Ling Chen , David Kaslow , John Shiver , Timothy Toner , Danilo Casimiro
发明人： Emilio Emini , Rima Youil , Andrew Bett , Ling Chen , David Kaslow , John Shiver , Timothy Toner , Danilo Casimiro
IPC分类号： C12Q1/68 , C12N15/00
CPC分类号： C12N15/86 , A61K39/12 , A61K39/21 , A61K2039/5256 , A61K2039/53 , A61K2039/545 , A61K2039/55555 , A61K2039/57 , C07K14/005 , C12N7/00 , C12N15/63 , C12N2710/10343 , C12N2710/10351 , C12N2740/16122 , C12N2740/16134 , C12N2740/16222 , C12N2740/16234 , C12N2740/16322 , C12N2740/16334 , C12N2830/42
摘要： First generation adenoviral vectors and associated recombinant adenovirus-based HIV vaccines which show enhanced stability and growth properties and greater cellular-mediated immunity are described within this specification. These adenoviral vectors are utilized to generate and produce through cell culture various adenoviral-based HIV-1 vaccines which contain HIV-1 gag, HIV-1 pol and/or HIV-1 nef polynucleotide pharmaceutical products, and biologically relevant modifications thereof. These adenovirus vaccines, when directly introduced into living vertebrate tissue, preferably a mammalian host such as a human or a non-human mammal of commercial or domestic veterinary importance, express the HIV1-Gag, Pol and/or Nef protein or biologically modification thereof, inducing a cellular immune response which specifically recognizes HIV-1. The exemplified polynucleotides of the present invention are synthetic DNA molecules encoding HIV-1 Gag, encoding codon optimized HIV-1 Pol, derivatives of optimized HIV-1 Pol (including constructs wherein protease, reverse transcriptase, RNAse H and integrase activity of HIV-1 Pol is inactivated), HIV-1 Nef and derivatives of optimized HIV-1 Nef, including nef mutants which effect wild type characteristics of Nef, such as myristylation and down regulation of host CD4. The adenoviral vaccines of the present invention, when administered alone or in a combined modality regime, will offer a prophylactic advantage to previously uninfected individuals and/or provide a therapeutic effect by reducing viral load levels within an infected individual, thus prolonging the asymptomatic phase of HIV-1 infection.
摘要翻译：在本说明书中描述了显示增强的稳定性和生长特性以及更大的细胞介导的免疫的第一代腺病毒载体和相关重组腺病毒的HIV疫苗。这些腺病毒载体用于通过细胞培养产生和产生各种含有HIV-1 gag，HIV-1 pol和/或HIV-1 nef多核苷酸药物产品的基于腺病毒的HIV-1疫苗及其生物相关的修饰。这些腺病毒疫苗当直接引入活的脊椎动物组织中时，优选哺乳动物宿主例如具有商业或家庭兽医重要性的人或非人哺乳动物，表达HIV1-Gag，Pol和/或Nef蛋白或其生物修饰，诱导特异性识别HIV-1的细胞免疫应答。本发明的示例性多核苷酸是编码HIV-1Gag的编码密码子优化的HIV-1 Pol的合成DNA分子，其优化的HIV-1 Pol的衍生物（包括其中蛋白酶，逆转录酶，RNAse H和HIV-1的整合酶活性 Pol被灭活），HIV-1 Nef和优化的HIV-1 Nef的衍生物，包括影响Nef野生型特征的nef突变体，如主体CD4的肉豆蔻酰化和下调。本发明的腺病毒疫苗当单独施用或以组合的方式给药时，将对先前未感染的个体提供预防优势，和/或通过减少被感染个体内的病毒载量水平提供治疗效果，从而延长无症状期 HIV-1感染。

3. 发明申请

US20050070017A1 Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-Gag, Pol, Nef and modifications 审中-公开
标题翻译：表达密码子优化的HIV1-Gag，Pol，Nef和修饰的增强的第一代腺病毒疫苗
公开(公告)号：US20050070017A1
公开(公告)日：2005-03-31
申请号：US10636730
申请日：2003-08-07
申请人： Emilio Emini , Rima Youil , Andrew Bett , Ling Chen , David Kaslow , John Shiver , Timothy Toner , Danilo Casimiro
发明人： Emilio Emini , Rima Youil , Andrew Bett , Ling Chen , David Kaslow , John Shiver , Timothy Toner , Danilo Casimiro
IPC分类号： C07K14/16 , C12N7/01 , C12N7/02 , C12N15/861 , A61K39/12 , C12N7/00
CPC分类号： C12N7/00 , A61K2039/5256 , A61K2039/53 , A61K2039/545 , A61K2039/57 , C07K14/005 , C12N15/86 , C12N2710/10343 , C12N2710/10351 , C12N2740/16122 , C12N2740/16134 , C12N2740/16322 , C12N2740/16334 , C12N2830/42
摘要： First generation adenoviral vectors and associated recombinant adenovirus-based HIV vaccines which show enhanced stability and growth properties and greater cellular-mediated immunity are described within this specification. These adenoviral vectors are utilized to generate and produce through cell culture various adenoviral-based HIV-1 vaccines which contain HIV-1 gag, HIV-1 pol and/or HIV-1 nef polynucleotide pharmaceutical products, and biologically relevant modifications thereof. These adenovirus vaccines, when directly introduced into living vertebrate tissue, preferably a mammalian host such as a human or a non-human mammal of commercial or domestic veterinary importance, express the HIV1-Gag, Pol and/or Nef protein or biologically modification thereof, inducing a cellular immune response which specifically recognizes HIV-1. The exemplified polynucleotides of the present invention are synthetic DNA molecules encoding HIV-1 Gag, encoding codon optimized HIV-1 Pol, derivatives of optimized HIV-1 Pol (including constructs wherein protease, reverse transcriptase, RNAse H and integrase activity of HIV-1 Pol is inactivated), HIV-1 Nef and derivatives of optimized HIV-1 Nef, including nef mutants which effect wild type characteristics of Nef, such as myristylation and down regulation of host CD4. The adenoviral vaccines of the present invention, when administered alone or in a combined modality regime, will offer a prophylactic advantage to previously uninfected individuals and/or provide a therapeutic effect by reducing viral load levels within an infected individual, thus prolonging the asymptomatic phase of HIV-1 infection.
摘要翻译：在本说明书中描述了显示增强的稳定性和生长特性以及更大的细胞介导的免疫的第一代腺病毒载体和相关重组腺病毒的HIV疫苗。这些腺病毒载体用于通过细胞培养产生和产生各种含有HIV-1 gag，HIV-1 pol和/或HIV-1 nef多核苷酸药物产品的基于腺病毒的HIV-1疫苗及其生物相关的修饰。这些腺病毒疫苗当直接引入活的脊椎动物组织中时，优选哺乳动物宿主例如具有商业或家庭兽医重要性的人或非人哺乳动物，表达HIV1-Gag，Pol和/或Nef蛋白或其生物修饰，诱导特异性识别HIV-1的细胞免疫应答。本发明的示例性多核苷酸是编码HIV-1Gag的编码密码子优化的HIV-1 Pol的合成DNA分子，其优化的HIV-1 Pol的衍生物（包括其中蛋白酶，逆转录酶，RNAse H和HIV-1的整合酶活性 Pol被灭活），HIV-1 Nef和优化的HIV-1 Nef的衍生物，包括影响Nef野生型特征的nef突变体，如主体CD4的肉豆蔻酰化和下调。本发明的腺病毒疫苗当单独施用或以组合的方式给药时，将对先前未感染的个体提供预防优势，和/或通过减少被感染个体内的病毒载量水平提供治疗效果，从而延长无症状期 HIV-1感染。

4. 发明授权

US06733993B2 Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications 失效
标题翻译：增强的第一代腺病毒疫苗表达密码子优化的HIV1-gag，pol，nef和修饰
公开(公告)号：US06733993B2
公开(公告)日：2004-05-11
申请号：US09952060
申请日：2001-09-14
申请人： Emilio A. Emini , Rima Youil , Andrew J. Bett , Ling Chen , David C. Kaslow , John W. Shiver , Timothy J. Toner , Danilo R. Casimiro
发明人： Emilio A. Emini , Rima Youil , Andrew J. Bett , Ling Chen , David C. Kaslow , John W. Shiver , Timothy J. Toner , Danilo R. Casimiro
IPC分类号： C12P2106
CPC分类号： C12N7/00 , A61K2039/5256 , A61K2039/53 , A61K2039/545 , A61K2039/57 , C07K14/005 , C12N15/86 , C12N2710/10343 , C12N2710/10351 , C12N2740/16122 , C12N2740/16134 , C12N2740/16322 , C12N2740/16334 , C12N2830/42
摘要： First generation adenoviral vectors and associated recombinant adenovirus-based HIV vaccines which show enhanced stability and growth properties and greater cellular-mediated immunity are described within this specification. These adenoviral vectors are utilized to generate and produce through cell culture various adenoviral-based HIV-1 vaccines which contain HIV-1 gag, HIV-1 pol and/or HIV-1 nef polynucleotide pharmaceutical products, and biologically relevant modifications thereof. These adenovirus vaccines, when directly introduced into living vertebrate tissue, preferably a mammalian host such as a human or a non-human mammal of commercial or domestic veterinary importance, express the HIV1-Gag, Pol and/or Nef protein or biologically modification thereof, inducing a cellular immune response which specifically recognizes HIV-1. The exemplified polynucleotides of the present invention are synthetic DNA molecules encoding HIV-1 Gag, encoding codon optimized HIV-1 Pol, derivatives of optimized HIV-1 Pol (including constructs wherein protease, reverse transcriptase, RNAse H and integrase activity of HIV-1 Pol is inactivated), HIV-1 Nef and derivatives of optimized HIV-1 Nef, including nef mutants which effect wild type characteristics of Nef, such as myristylation and down regulation of host CD4. The adenoviral vaccines of the present invention, when administered alone or in a combined modality regime, will offer a prophylactic advantage to previously uninfected individuals and/or provide a therapeutic effect by reducing viral load levels within an infected individual, thus prolonging the asymptomatic phase of HIV-1 infection.
摘要翻译：在本说明书中描述了显示增强的稳定性和生长特性以及更大的细胞介导的免疫的第一代腺病毒载体和相关重组腺病毒的HIV疫苗。这些腺病毒载体用于通过细胞培养产生和产生各种含有HIV-1 gag，HIV-1 pol和/或HIV-1 nef多核苷酸药物产品的基于腺病毒的HIV-1疫苗及其生物相关的修饰。这些腺病毒疫苗当直接引入活的脊椎动物组织中时，优选哺乳动物宿主例如具有商业或家庭兽医重要性的人或非人哺乳动物，表达HIV1-Gag，Pol和/或Nef蛋白或其生物修饰，诱导特异性识别HIV-1的细胞免疫应答。本发明的示例性多核苷酸是编码HIV-1Gag的编码密码子优化的HIV-1 Pol的合成DNA分子，其优化的HIV-1 Pol的衍生物（包括其中蛋白酶，逆转录酶，RNAse H和HIV-1的整合酶活性 Pol被灭活），HIV-1 Nef和优化的HIV-1 Nef的衍生物，包括影响Nef野生型特征的nef突变体，如主体CD4的肉豆蔻酰化和下调。本发明的腺病毒疫苗当单独施用或以组合的方式给药时，将对先前未感染的个体提供预防优势，和/或通过减少被感染个体内的病毒载量水平提供治疗效果，从而延长无症状期 HIV-1感染。

5. 外观设计

USD917496S1 Tablet computer stand 有权
公开(公告)号：USD917496S1
公开(公告)日：2021-04-27
申请号：US29683529
申请日：2019-03-14
申请人： Ling Chen
设计人： Ling Chen

6. 外观设计

USD842261S1 Wireless transmitter 有权
公开(公告)号：USD842261S1
公开(公告)日：2019-03-05
申请号：US29624012
申请日：2017-10-30
申请人： Ling Chen
设计人： Ling Chen
摘要： FIG. 1 is a perspective view of a wireless transmitter showing my new design;
FIG. 2 is a front elevational view thereof;
FIG. 3 is a rear elevational view thereof;
FIG. 4 is a left side elevational view thereof;
FIG. 5 is a right side elevational view thereof;
FIG. 6 is a top plan view thereof; and,
FIG. 7 is a bottom plan view thereof.

7. 发明授权

US09745530B2 Production of biodiesel from scum 有权
公开(公告)号：US09745530B2
公开(公告)日：2017-08-29
申请号：US15019707
申请日：2016-02-09
申请人： Rongsheng Ruan , Min Min Addy , Yong Nie , Erik Andrew Anderson , Chonghao Bi , Dong Li , Ling Chen
发明人： Rongsheng Ruan , Min Min Addy , Yong Nie , Erik Andrew Anderson , Chonghao Bi , Dong Li , Ling Chen
IPC分类号： C10L1/08 , C11B13/00 , C11B3/04 , C07C67/02 , C11C3/02 , C11C3/06 , C11C3/00
CPC分类号： C10L1/08 , C07C67/02 , C10L1/026 , C10L2200/0476 , C10L2270/026 , C10L2290/06 , C10L2290/08 , C10L2290/12 , C10L2290/543 , C10L2290/545 , C11B3/04 , C11B13/00 , C11C3/003 , C11C3/02 , C11C3/06 , Y02E50/13 , Y02W30/74
摘要： A method for production of a biodiesel is described herein. The method for production of a biodiesel comprises (a) separating solids from a waste oil composition to provide a clarified oil composition; (b) acidifying the clarified oil composition to produce an acidified oil composition including free fatty acids derived from the waste oil; (c) converting at least a portion of the free fatty acids in the acidified oil composition to glycerides to provide a glyceride composition; and (d) reacting at least a portion of the glycerides in the glyceride composition with methanol to form fatty acid methyl ester to provide a biodiesel composition.

8. 发明申请

US20170157144A1 PREPARATION METHOD FOR ANTITHYROID OINTMENT FOR EXTERNAL APPLICATION 有权
公开(公告)号：US20170157144A1
公开(公告)日：2017-06-08
申请号：US15325444
申请日：2015-07-16
申请人： Ling Chen
发明人： Ling Chen
IPC分类号： A61K31/573 , A61K31/4172 , A61K31/513 , A61K31/56 , A61K47/44 , A61K9/06 , A61K47/34 , A61K47/14 , A61K47/22 , A61K47/20 , A61K47/30 , A61K31/4164 , A61K47/10
CPC分类号： A61K31/573 , A61K9/06 , A61K31/4164 , A61K31/4172 , A61K31/513 , A61K31/56 , A61K31/58 , A61K45/06 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/20 , A61K47/22 , A61K47/26 , A61K47/30 , A61K47/34 , A61K47/44 , A61K2300/00
摘要： A preparation method for an antithyroid ointment for external application is provided. The ointment includes the following components by mass percentage: 0.01-10% gluco corticoid, 1-15% antithyroid drug, 0.1-30% percutaneous penetration enhancer, 10-30% oleaginous base and 4-40% water-soluble base. The method includes: mixing the glucocorticoid and a drug carrier material so as to evenly disperse the glucocorticoids on the drug carrier material to obtain a glucocorticoid component; placing and evenly mixing an antithyroid drug and other ingredients in distilled water, and heating to 80° C. and evenly mixing to obtain a water phase; melting an oleaginous base and a percutaneous penetration enhancer at 80° C. and evenly mixing to obtain an oil phase; maintaining at 80° C. and pouring the oil phase into the water phase, and evenly stirring; adding the glucocorticoid component when the temperature drops to 40° C.; and evenly and sufficiently stirring until cooled to obtain an ointment.

9. 发明申请

US20160230106A1 PRODUCTION OF BIODIESEL FROM SCUM 有权
标题翻译：从SCUM生产生物体
公开(公告)号：US20160230106A1
公开(公告)日：2016-08-11
申请号：US15019707
申请日：2016-02-09
申请人： Rongsheng Ruan , Min Min Addy , Yong Nie , Erik Andrew Anderson , Chonghao Bi , Dong Li , Ling Chen
发明人： Rongsheng Ruan , Min Min Addy , Yong Nie , Erik Andrew Anderson , Chonghao Bi , Dong Li , Ling Chen
IPC分类号： C10L1/08 , C11B3/04
CPC分类号： C10L1/08 , C07C67/02 , C10L1/026 , C10L2200/0476 , C10L2270/026 , C10L2290/06 , C10L2290/08 , C10L2290/12 , C10L2290/543 , C10L2290/545 , C11B3/04 , C11B13/00 , C11C3/003 , C11C3/02 , C11C3/06 , Y02E50/13 , Y02W30/74
摘要： A method for production of a biodiesel is described herein. The method for production of a biodiesel comprises (a) separating solids from a waste oil composition to provide a clarified oil composition; (b) acidifying the clarified oil composition to produce an acidified oil composition including free fatty acids derived from the waste oil; (c) converting at least a portion of the free fatty acids in the acidified oil composition to glycerides to provide a glyceride composition; and (d) reacting at least a portion of the glycerides in the glyceride composition with methanol to form fatty acid methyl ester to provide a biodiesel composition.
摘要翻译：本文描述了生产生物柴油的方法。生产生物柴油的方法包括（a）从废油组合物中分离固体以提供澄清的油组合物; （b）使澄清的油组合物酸化以产生包含源自废油的游离脂肪酸的酸化油组合物; （c）将酸化油组合物中的游离脂肪酸的至少一部分转化为甘油酯以提供甘油酯组合物; 和（d）使甘油酯组合物中的至少一部分甘油酯与甲醇反应以形成脂肪酸甲酯以提供生物柴油组合物。

10. 发明申请

US20150047371A1 BONDED La(Fe,Si)13-BASED MAGNETOCALORIC MATERIAL AND PREPARATION AND USE THEREOF 审中-公开
标题翻译：粘结La（Fe，Si）13基磁性材料及其制备及其应用
公开(公告)号：US20150047371A1
公开(公告)日：2015-02-19
申请号：US14359685
申请日：2012-05-17
申请人： Fengxia Hu , Ling Chen , Lifu Bao , Jing Wang , Baogen Shen , Jirong Sun , Huayang Gong
发明人： Fengxia Hu , Ling Chen , Lifu Bao , Jing Wang , Baogen Shen , Jirong Sun , Huayang Gong
IPC分类号： H01F1/01 , F25B21/00
CPC分类号： H01F1/015 , F25B21/00 , F25B2321/002
摘要： Provided is a high-strength, bonded La(Fe, Si)13-based magnetocaloric material, as well as a preparation method and use thereof. The magnetocaloric material comprises magnetocaloric alloy particles and an adhesive agent, wherein the particle size of the magnetocaloric alloy particles is less than or equal to 800 μm and are bonded into a massive material by the adhesive agent; the magnetocaloric alloy particle has a NaZn13-type structure and is represented by a chemical formula of La1-xRx(Fe1-p-qCopMnq)13-ySiyAα, wherein R is one or more selected from elements cerium (Ce), praseodymium (Pr) and neodymium (Nd), A is one or more selected from elements C, H and B, x is in the range of 0≦x≦0.5, y is in the range of 0.8≦y≦2, p is in the range of 0≦p≦0.2, q is in the range of 0≦q≦0.2, α is in the range of 0≦α≦3.0. Using a bonding and thermosetting method, and by means of adjusting the forming pressure, thermosetting temperature, and thermosetting atmosphere, etc., a high-strength, bonded La(Fe, Si)13-based magnetocaloric material can be obtained, which overcomes the frangibility, the intrinsic property, of the magnetocaloric material. At the same time, the magnetic entropy change remains substantially the same, as compared with that before the bonding. The magnetic hysteresis loss declines as the forming pressure increases. And the effective refrigerating capacity, after the maximum loss being deducted, remains unchanged or increases.
摘要翻译：提供高强度的La（Fe，Si）13基磁热材料及其制备方法和用途。磁热材料包括磁热合金颗粒和粘合剂，其中磁热合金颗粒的颗粒尺寸小于或等于800μm，并通过粘合剂粘合成块状材料; 磁热合金颗粒具有NaZn13型结构，并且由La1-xRx（Fe1-p-qCopMnq）13-ySiyAα的化学式表示，其中R是选自元素铈（Ce），镨（Pr）和钕（Nd），A是选自元素C，H和B中的一种或多种，x在0和nlE的范围内; x和nlE; 0.5，y在0.8和nlE的范围内; y和nlE; 2，p在 0＆nlE; p＆nlE; 0.2，q在0和nlE的范围内; q＆nlE; 0.2，α在0＆lt; nEE;α＆nlE; 3.0的范围内。使用粘结和热固化方法，通过调整成型压力，热固化温度和热固性气氛等，可以获得高强度的La（Fe，Si）13基磁热材料，克服了易磁性，内在性质，磁热材料。同时，与接合前相比，磁熵变保持基本相同。随着成形压力的增加，磁滞损耗下降。扣除最大损失后的有效制冷量保持不变或增加。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式